Once-daily therapy: Less is more

Abstract

Over the last 20 years, a trend towards regimens with less frequent dosing has been observed across medicine. Recent surveys of people with HIV indicate that there is a strong preference for once-daily dosing and compact therapy. Four antiretrovirals (tenofovir, didanosine, lamivudine and efavirenz) are now available as once-a-day therapies. The range of once-daily options is expanding rapidly, with the potential for two lines of once-daily therapy to be available in the next 12–18 months.